Leveraging Pepper Bio’s transomics platform, Dean Felsher’s research team will translate academic findings for the development of more efficacious therapies for lymphoma and hepatocellular carcinoma
Today, Pepper Bio, the world’s first transomics drug discovery company, announced a collaboration with the Dean Felsher Laboratory at Stanford University. Leveraging Pepper Bio’s unique platform on phosphoproteomics, the two teams aim to identify and validate novel targets for hepatocellular carcinoma and lymphoma within the year.
Read on for the full press release.
Source: WebWire // See original post here.